^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
PD-L1 ≥50% First-Line Therapy....The following regimens added as Other Recommended...Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel (category 2B)...Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + pemetrexed (nonsquamous) (category 2B).
Secondary therapy:
carboplatin; cisplatin; pemetrexed; carboplatin + albumin-bound paclitaxel
